{"id":566564,"date":"2026-09-09T23:00:00","date_gmt":"2026-09-09T21:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/personalized-therapy-in-the-age-of-targeted-drugs\/"},"modified":"2026-09-17T21:44:26","modified_gmt":"2026-09-17T19:44:26","slug":"personalized-therapy-in-the-age-of-targeted-drugs","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/personalized-therapy-in-the-age-of-targeted-drugs\/","title":{"rendered":"Personalized Therapy in the Age of Targeted Drugs"},"content":{"rendered":"\n

New data on the use of pirtobrutinib in treatment-naive patients with chronic lymphocytic leukemia were presented at the 2026 ASCO Annual Meeting. The results from the Phase 3 studies BRUIN CLL-313 and BRUIN CLL-314 provide current insights into the efficacy and safety of non-covalent BTK inhibition as a first-line treatment.<\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

New data on the use of pirtobrutinib in treatment-naive patients with chronic lymphocytic leukemia were presented at the 2026 ASCO Annual Meeting. The results from the Phase 3 studies BRUIN……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Chronic Lymphocytic Leukemia (CLL)","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11548,11513,11353,11370,11503],"tags":[101565,102025,102028,102001,85926,102016,102030,102014,102003,102020,102008,102019,102018,11934,102017,102034,102005,102024,102013,92355,102010,102015,102007,55707,102012,102022,102032],"powerkit_post_featured":[],"class_list":["post-566564","post","type-post","status-publish","format-standard","category-rx-en","category-congress-reports","category-hematology","category-oncology","category-studies","tag-asco-annual-meeting-2026","tag-bcl2-inhibitors","tag-bcr-signaling-pathway","tag-bruin-cll-314","tag-btk-inhibitors","tag-c481s-mutation","tag-cardiovascular-side-effects","tag-cll-treatment","tag-cll-sll","tag-complex-karyotype","tag-covalent-btk-inhibitors","tag-del11q","tag-del17p","tag-first-line-therapy","tag-ighv-status","tag-molecular-risk-factors","tag-non-covalent-btk-inhibition","tag-notch1-mutations","tag-overall-response-rate-orr","tag-pirtobrutinib","tag-progression-free-survival-pfs-2","tag-resistance-mutations","tag-reversible-btk-inhibition","tag-safety-profile","tag-time-to-response-dor","tag-tp53-aberrations","tag-treatment-discontinuations","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-09-25 10:07:06","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":566571,"slug":"la-therapie-personnalisee-a-lere-des-medicaments-cibles","post_title":"La th\u00e9rapie personnalis\u00e9e \u00e0 l'\u00e8re des m\u00e9dicaments cibl\u00e9s","href":"https:\/\/medizinonline.com\/fr\/la-therapie-personnalisee-a-lere-des-medicaments-cibles\/"},"it_IT":{"locale":"it_IT","id":566580,"slug":"la-terapia-personalizzata-nellera-dei-farmaci-mirati","post_title":"La terapia personalizzata nell\u2019era dei farmaci mirati","href":"https:\/\/medizinonline.com\/it\/la-terapia-personalizzata-nellera-dei-farmaci-mirati\/"},"pt_PT":{"locale":"pt_PT","id":566594,"slug":"terapia-individualizada-na-era-dos-principios-ativos-direcionados","post_title":"Terapia individualizada na era dos princ\u00edpios ativos direcionados","href":"https:\/\/medizinonline.com\/pt-pt\/terapia-individualizada-na-era-dos-principios-ativos-direcionados\/"},"es_ES":{"locale":"es_ES","id":566561,"slug":"terapia-individualizada-en-la-era-de-los-farmacos-dirigidos","post_title":"Terapia individualizada en la era de los f\u00e1rmacos dirigidos","href":"https:\/\/medizinonline.com\/es\/terapia-individualizada-en-la-era-de-los-farmacos-dirigidos\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/566564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=566564"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/566564\/revisions"}],"predecessor-version":[{"id":566569,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/566564\/revisions\/566569"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=566564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=566564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=566564"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=566564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}